MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Chicago, IL, US. The stock last traded at $1.36, down 1.09% on the session, giving a market capitalisation of $83.0M. On trailing twelve-month figures it carries a trailing P/E of -2.15, a net margin of 0.0%. Its beta of 0.25 implies it has historically moved less than the broad market.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
MAIA Biotechnology, Inc. is most often compared with the following Healthcare names: